M
Miracor Medical Systems
Cardiac therapy improving myocardial microcirculatory function
About Miracor Medical Systems
Miracor Medical is a Belgian medical device company founded in 2008 by Professor Dr. Dr. Werner Mohl, Earlybird, and Delta Partners. The company develops and commercializes the PiCSO (Pressure-controlled intermittent Coronary Sinus Occlusion) Impulse System, a therapeutic device for patients with impaired cardiac function. The current CEO is Olivier Delporte.
The company's core product, the PiCSO Impulse System, is designed as an adjunctive therapy used during Percutaneous Coronary Intervention (PCI) for patients suffering from acute myocardial infarction (heart attack). The system consists of a driving console and a catheter with a balloon that is positioned in the coronary sinus. It works by intermittently occluding the coronary sinus, which increases pressure and redistributes blood flow to damaged areas of the heart muscle, aiming to clear microvascular obstruction and reduce the size of the infarct (damaged tissue). A reduction in infarct size is strongly associated with a lower risk of heart failure and mortality.
Miracor operates in the cardiovascular medical device market, targeting interventional cardiologists as its primary clients. Its business model centers on the sale of the PiCSO console and the associated single-use catheters. The company has achieved significant milestones, including receiving a CE Mark for the PiCSO Impulse System in June 2020, allowing for commercialization in Europe, and gaining 'Breakthrough Device Designation' from the U.S. Food and Drug Administration (FDA) in 2019. The company has been actively conducting clinical trials across Europe to gather further evidence of the therapy's benefits and received FDA IDE approval for a pivotal study in the US in 2022.
Since its founding, Miracor Medical has raised approximately $117 million in funding over eight rounds from a mix of venture capital firms and public investors, including Ming Capital, BioMedPartners, Peppermint Venture Partners, and Yong hua. The company was initially based in Vienna, Austria, before relocating its headquarters to Awans, Belgium, in 2018 to support its growth and development phase.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 29.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Cardiology and cardiovascular, Patient Care, Sustainable Development Goals, Hard Tech, Horizon Europe, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Sep 2020 | $26M | $106M | Earlybird Venture Capital · Quest for Growth · Noshaq · SFPIM | — |
| SERIES DOther financing | Sep 2018 | $5.5M | $22M | Quest for Growth · Noshaq · SFPIM · Ming Capital | — |
Growth signals
Latest recorded traffic for Miracor Medical Systems is 2.1K monthly website visits, up 40% over the last three months. Miracor Medical Systems's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Miracor Medical Systems in the Awans ecosystem
The Miracor Medical Systems office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Austrian Research Promotion Agency (FFG)
MedTech Innovator
Series A6 investors entered at this stage
Earlybird Venture Capital
Delta Partners
Austria Wirtschaftsservice
SHS Capital
aws Gründungsfonds
BioMedVC
Series B and later7 investors entered at this stage
Peppermint Venture Partners
Ming Capital
Noshaq
Wallonie Entreprendre
SFPIM
Quest for Growth
Yonghua Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Miracor Medical Systems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Miracor Medical Systems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










